Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM310 in chronic rhinosinusitis with nasal polyps (Phase II)
CTR20210321Phase 2Completed
- Sponsor
- Keymed Biosciences
- Start
- Feb 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of stapokibart in chronic rhinosinusitis with nasal polyps (CRSwNP), sponsored by Keymed Biosciences. Started Feb 2021; status: completed.
02
Drugs
stapokibart
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on CTR20210321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210321.